Vest Financial LLC Has $81.29 Million Stake in Johnson & Johnson $JNJ

Vest Financial LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 3.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 438,402 shares of the company’s stock after selling 14,321 shares during the quarter. Johnson & Johnson comprises 1.1% of Vest Financial LLC’s portfolio, making the stock its 8th biggest holding. Vest Financial LLC’s holdings in Johnson & Johnson were worth $81,288,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Clark Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after buying an additional 3,025 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after purchasing an additional 94,957 shares in the last quarter. Talbot Financial LLC boosted its holdings in shares of Johnson & Johnson by 4.6% during the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock valued at $25,667,000 after purchasing an additional 6,143 shares during the last quarter. Liberty One Investment Management LLC grew its position in shares of Johnson & Johnson by 83.9% during the third quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock valued at $68,040,000 after purchasing an additional 167,353 shares in the last quarter. Finally, Winnow Wealth LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth about $295,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $218.58 on Friday. The company has a market capitalization of $526.62 billion, a P/E ratio of 19.78, a P/E/G ratio of 2.24 and a beta of 0.34. The company’s 50-day simple moving average is $207.86 and its two-hundred day simple moving average is $188.48. Johnson & Johnson has a one year low of $141.50 and a one year high of $222.17. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.Johnson & Johnson’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Royal Bank Of Canada set a $240.00 price target on Johnson & Johnson in a research note on Wednesday, December 17th. Morgan Stanley increased their target price on Johnson & Johnson from $197.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday. Barclays boosted their price target on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 30th. TD Cowen increased their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $220.45.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 results and 2026 outlook showed strength — revenue beat and management set FY2026 EPS and sales guidance largely above consensus, underpinning confidence in growth beyond legacy drugs. MarketBeat JNJ overview and earnings
• Positive Sentiment: Analysts are lifting targets — notably Scotiabank to $265 (sector outperform), signaling sizable upside from current levels and helping sentiment. Scotiabank price target raise
• Positive Sentiment: Dividend pedigree remains a tailwind — J&J is a Dividend King with 63+ years of raises and a ~2.4–2.5% yield, supporting income-focused buying. Fool: Dividend King story
• Neutral Sentiment: MedTech and oncology are offsetting biosimilar pressure — MedTech sales and oncology (e.g., Darzalex) are growing, which supports the firm’s pivot post-consumer spin-off but execution risk remains. PYMNTS: Product launches & growth
• Neutral Sentiment: Technical and institutional narratives are constructive — a MarketBeat piece flagged a trend-following buy setup and continued institutional accumulation, which can amplify momentum-driven buying. MarketBeat trend signal
• Negative Sentiment: Legal/talc developments remain a headline risk — a court ruling allowed plaintiffs’ expert testimony in the talc MDL, a development that could raise litigation exposure or near-term volatility. GlobeNewsWire: talc litigation update
• Negative Sentiment: Stelara patent loss and biosimilar competition have materially pressured Stelara sales (multi‑quarter declines), a structural headwind that management is addressing via other franchises but which limits near-term upside. Zacks: Stelara pressure & offsetting oncology

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.